Ignite Creation Date:
2024-05-05 @ 11:28 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00047710
Status:
COMPLETED
Last Update Posted:
2012-08-01
First Post:
2002-10-14
Brief Title:
Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Study Overview
Official Title:
A Phase I Trial of Concurrent RHUMAB VEGF BEVACIZUMAB and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer
Status:
COMPLETED
Status Verified Date:
2012-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical research study is to find the highest safe dose of the drug Bevacizumab that can be given in combination with chemoradiation for the treatment of pancreatic cancer The effect that this combination treatment has on the tumor will also be studied
Detailed Description:
This study administers 504 Gy of radiation for unresectable pancreatic cancer with concurrent capecitabine and an experimental drug Bevacizumab The drug is an antiangiogenic agent kills tumor blood vessels and has been shown in preclinical models to enhance the antitumor effect of radiation and chemotherapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None